(NASDAQ: ALLO) Allogene Therapeutics's forecast annual revenue growth rate of 1,347.44% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Allogene Therapeutics's revenue in 2025 is $22,000.On average, 1 Wall Street analysts forecast ALLO's revenue for 2025 to be $21,726,474, with the lowest ALLO revenue forecast at $21,726,474, and the highest ALLO revenue forecast at $21,726,474. On average, 2 Wall Street analysts forecast ALLO's revenue for 2026 to be $34,762,358, with the lowest ALLO revenue forecast at $21,726,474, and the highest ALLO revenue forecast at $47,798,242.
In 2027, ALLO is forecast to generate $16,099,968,880 in revenue, with the lowest revenue forecast at $6,387,583,297 and the highest revenue forecast at $30,462,688,915.